



Publications and Presentations

Cancer

Irish W, Ryan M, Gache L, Gunnarsson C, Bell T, Shapiro M. **Acute Myeloid Leukemia: A Retrospective Claims Analysis of Resource Utilization and Expenditures for Newly Diagnosed Patients From First-Line Induction to Remission and Relapse.** *Curr Med Res Opin.* 2017;33(3):519-527.

Irish W, Ryan MP, Gache LM, Gunnarsson C, Bell T, Shapiro M. **Acute Myeloid Leukemia: A Retrospective Claims Analysis of Resource Utilization and Expenditures for De Novo Patients from First Line Induction to Remission and Relapse.** *Value Health.* 2016;19(3):A166.

Goldberg SL, Su Y, Gunnarsson C, Irish WD, Ryan M, Woloj M, Ferdinand R, Shapiro M. **The Effect of Vascular Occlusive Events on Discontinuation and Cost of Care in Patients Treated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.** *Blood.* 2015;126(23):2797.

Irish WD, Ryan M, Gache L, Gunnarsson C, Bell T, Shapiro M. **Acute Myeloid Leukemia (AML): A Retrospective Claims Analysis of Resource Utilization and Expenditures.** *Blood.* 2015;126(23):5633.

Mallow PJ, Chen J, Rizzo JA, Penrod JR, Trudel GC. **The Direct Healthcare Expenditures of Prostate Cancer by Disease Severity: Evidence from US National Survey Data.** *JHEOR.* 2015;3(1):83-96.

Goldberg SL, Su Y, Frame D, Ryan M, Irish WD, Gunnarsson C, Woloj M, Ferdinand R, Shapiro M. **Patient characteristics and adverse events (AEs) of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) in real world settings.** *Haematologica.* 2015;100(s1):441.

Goldberg SL, Su Y, Frame D, Ryan M, Irish WD, Gunnarsson C, Woloj GM, Ferdinand R, Shapiro M. **Patient characteristics and adverse events (AEs) of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) in real world settings.** *J Clin Oncol.* 2015;33(15_suppl):e18026.

Mallow PJ, Chen J, Rizzo JA, Zyczynski TM, Penrod JR, Trudel GC. **The direct healthcare cost of prostate cancer: evidence from US national survey data.** *Value Health.* 2013;16(3):A135.

Chen J, Mallow PJ, Rizzo JA, Zyczynski TM, Trudel GC, Penrod JR. **Cost of lost productivity due to prostate cancer: evidence from US national survey data.** *Value Health.* 2013;16(3):A135.

Rizzo JA, Chen J, Penrod JR, Mallow PJ, Trudel GC, Zyczynski TM. **The labor productivity effects of prostate cancer patients on spouses and other family members: evidence from US national survey data.** *Value Health.* 2013;16(3):A135.

Le TK, Zhang Y, Zyczynski TM. **Cost of metastatic castration-resistant prostate cancer in the United States.** *Value Health.* 2013;16(3):A136.

Zyczynski TM, Trudel GC, Chen J, Mallow PJ, Penrod JR, Rizzo JA. **The impact of prostate cancer on quality of life.** *Value Health.* 2013;16(3):A136.

Cardiovascular Disease

McCullough PA, David G, Todoran T, Brilakis ES, Ryan MP, Gunnarsson C. **Iso-Osmolar Contrast Media and Adverse Renal and Cardiac Events after Percutaneous Cardiovascular Intervention.** Poster accepted for presentation at *ISPOR 20th Annual European Congress*, November 4-8, 2017, Glasgow, Scotland.

Jarman JW, Hunter TD, Hussain W, March JL, Wong T, Markides V. **Stroke rates before and after atrial fibrillation ablation and in propensity-matched controls in the UK.** *Pragmat Obs Res.* 2017;8:107-118.

Jarman JW, Hunter TD, Hussain W, March JL, Wong T, Markides V. **Mortality, stroke and heart failure in atrial fibrillation cohorts after ablation versus propensity-matched cohorts.** *Pragmat Obs Res.* 2017;8:99-106.

Gerdisch MW, Robinson SB, David G, Makepeace S, Ryan MP, Gunnarsson C. **Impact of the Adoption of Microplegia Delivery System: Clinical and Economic Analysis Using the Premier Database.** *Value Health.* 2017;20(5):A244.

Osorio J, Hunter TD, Bubien RS, Thorington S, Rajendra A, Arciniegas JG. **Efficiency and predictability in paroxysmal atrial fibrillation ablation with contact force catheter and stability module integration.** *Europace* 2017;19 (suppl_3):iii371-iii372.

Osorio J, Hunter T, Bubien RS, Thorington S, Rajendra A, Arciniegas J. **A comparison of paroxysmal atrial fibrillation ablation efficiency and clinical outcomes across technologies in a high-volume center.** *Europace.* 2017;19 (suppl_3):iii371.

De Potter T, Hunter TD, Boo LM, Chatzikyriakou S, Strisciuglio T, Silva Garcia E. **Ablation Efficiency with Contact Force Stability and Ablation Index in Paroxysmal Atrial Fibrillation.** *Heart Rhythm.* 2017;14(5S):S179.

Macle L, Frame D, Gache LM, Monir G, Pollak SJ, Boo LM. **Atrial Fibrillation Ablation using a Thermocool SmartTouch Catheter Compared to Non-Contact-Force Catheters: A Systematic Review and Meta-Analysis.** *Heart Rhythm.* 2017;14(5S):S461–S462.

Moore M, Barnhart GR, Chitwood WR Jr., Rizzo JA, Gunnarsson C, Palli SR, Grossi EA. **The economic value of rapid deployment aortic valve replacement via full sternotomy.** *J Comp Eff Res.* 2017;6(4):293-302.

Biviano AB, Hunter TD, Dandamudi G, Fishel RS, Gidney B, Herweg B, Oza SR, Patel AM, Wang H, Pollak SJ. **Healthcare Utilization and Quality of Life Improvement after Ablation for Paroxysmal AF in Younger and Older Patients.** *Pacing Clin Electrophysiol.* 2017;40(4):391-400.

Lip GY, Hunter TD, Quiroz ME, Ziegler PD, Turakhia MP. **Atrial Fibrillation Diagnosis Timing, Ambulatory ECG Monitoring Utilization, and Risk of Recurrent Stroke.** *Circ Cardiovasc Qual Outcomes.* 2017;10(1):e002864.

Moore M, Chen J, Mallow PJ, Rizzo JA. **The direct health-care burden of valvular heart disease: evidence from US national survey data.** *Clinicoecon Outcomes Res.* 2016;8:613-627.

Moore, M, Barnhart GR, Chitwood WR Jr., Rizzo JA, Gunnarsson C, Palli SR, Grossi EA. **The Economic Value of Rapid Deployment Aortic Valve Replacement via Full Sternotomy.** *Value Health.*2016;19(7):A645.

Lebehn M, Hunter T, Clancy S, Spies C. **Effects of anesthesia on cost and length of stay in patients undergoing Transcatheter Aortic Valve Replacement (TAVR) – Results from a Cohort Study.** *J Am Coll Cardiol.* 2016;68(18_S):B278.

Lebehn M, Hunter T, Clancy S, Spies C. **A comparison of the effects on length of stay and cost with percutaneous versus surgical cutdown femoral artery access in patients undergoing Transcatheter Aortic Valve Replacement – Results from a Cohort Study.** *J Am Coll Cardiol.* 2016;68(18_S):B152.

Sohail MR, Eby EL, Ryan MP, Gunnarsson C, Wright LA, Greenspon AJ. **Incidence, Treatment Intensity, and Incremental Annual Expenditures for Patients Experiencing a Cardiac Implantable Electronic Device Infection: Evidence from a Large US Payer Database 1-Year Post Implantation.** *Circ Arrhythm Electrophysiol.* 2016; 9(8):e003929.

Moore M, Barnhart GR, Chitwood WR Jr, Rizzo JA, Gunnarsson C, Palli SR, Grossi EA. **The economic value of INTUITY in aortic valve replacement.** *J Med Econ.* 2016;19(10):1011-1017.

Hunter TD, Palli SR, Rizzo, JA. **Cost comparison of radiofrequency catheter ablation versus cryoablation for atrial fibrillation in hospitals using both technologies.** *J Med Econ.* 2016;19(10):959-964.

Clancy S, Womeldorff J, Ryan MP. **Operating Room Variable Cost of Transcatheter Aortic Valve Replacement.** *Value Health.* 2016;19(3):A47.

Ladapo JA, Turakhia MP, Ryan MP, Mollenkopf SA, Reynolds ME. **Healthcare Utilization and Expenditures Associated With Remote Monitoring in Patients With Implantable Cardiac Devices.** *Am J Cardiol.* 2016;117(9):1455-1462.

Hunter TD, Palli S, Mallow PJ, Rizzo, JA. **Cost Comparison of Radiofrequency Catheter Ablation versus Cryoablation for Atrial Fibrillation in Hospitals Using Both Technologies.** *Heart Rhythm.* 2016;13(Supplement 5):S120.

Mallow PJ, Johnson M, Lim L, David G. **Contrast Media Selection in Inpatient Interventional Cardiovascular Procedures.** Oral presentation at *China Interventional Therapeutics (CIT 2016)*, March 17-20, 2016, Beijing, China.

Mallow PJ, Johnson M, Lim L, David G. **The Effect of the Choice of Contrast Media on Renal Failure Events in Inpatient Interventional & Diagnostic Cardiovascular Procedures.** Poster presented at *China Interventional Therapeutics (CIT 2016)*, March 17-20, 2016, Beijing, China.

Mallow PJ, Johnson M, Lim L, David G. **The Effect of the Choice of Contrast Media on Renal Failure Events in Inpatient Cardiovascular Procedures.** Poster presented at the *Cardio-Renal Metabolic Conference (CRSA)*, March 12, 2016, Scottsdale, AZ, USA.

Mallow PJ, Chen J, Moore M, Rizzo JA. **The Direct Healthcare Expenditures of Mitral Valve Disease: Evidence From US National Survey Data.** *Circ Cardiovasc Qual Outcomes.* 2016;9(Suppl_2):A258.

Chen J, Mallow PJ, Moore M, Rizzo JA. **The Direct Healthcare Expenditures of Aortic Valve Disease: Evidence From US National Survey Data.** *Circ Cardiovasc Qual Outcomes.* 2016;9(Suppl_2):A257.

Mallow PJ, Johnson M, Lim L, David G. **The Effect of the Choice of Contrast Media on Renal Failure Events in Inpatient Cardiovascular Procedures.** Poster presented at *AKI & CRRT 2016 21st International Conference on Advances in Critical Care Nephrology*, February 16-19, 2016, San Diego, CA, USA.

David G, Johnson M, Lim L, Mallow PJ. **The Effect of the Choice of Contrast Media on Contrast-Induced Acute Kidney Injury Events in Inpatient Interventional or Diagnostic Cardiovascular Procedures.** *J Am Coll Cardiol.* 2015;66(15_S):B151-B152.

Nazarian S, Reynolds MR, Ryan MP, Wolff SD, Mollenkopf SA, Turakhia MP. **Utilization and likelihood of radiologic diagnostic imaging in patients with implantable cardiac defibrillators.** *J Magn Reson Imaging.* 2015;43(1):115-127.

Chyou JY, Hunter TD, Mollenkopf SA, Turakhia MP, Reynolds MR. **Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients.** *J Am Heart Assoc.* 2015;23;4(7):e001723.

Khaykin Y, Mallow PJ, Rizzo JA, Verma A, Chun L, Olesovsky S, Reynolds MR. **Cost-effectiveness of Catheter Ablation versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective.** *JHEOR.* 2015;3(1):1-12.

Mallow P, Ryan M, Johnson M, Lim L, David G. **The effect of the choice of contrast media on MARCE events in angioplasty procedures.** *EuroIntervention.* 2015. Abstracts EuroPCR May 2015:POS062.

Mallow P, Ryan M, Johnson M, Lim L, David G. **The effect of the choice of contrast media on kidney events in angioplasty procedures.** *EuroIntervention.* 2015. Abstracts EuroPCR May 2015:POS064.

Nazarian S, Reynolds MR, Ryan MP, Wolff SD, Mollenkopf S, Turakhia MP. **Evidence of a gap in care: utilization of Radiologic Diagnostic imaging in patients with and without implantable defibrillators.** *Value Health.* 2015;18(3):A47.

Gunnarsson C, Lim S, David G, Riebman JB, Martin L, Kocharian R. **The Incremental Cost of Reoperations for Bleeding Events in Cardiac and Vascular Reconstructive Surgery.** *Value Health.* 2015;18(3):A140.

Rizzo JA, Chen J, Mallow PJ, Moore M. **The Total Direct Healthcare Cost of Aortic and Mitral Valvular Disease: Evidence from US National Survey Data.** *Value Health.* 2015;18(3):A144.

Jarman JWE, March JL, Hunter TD. **Stroke Rates after Pulmonary Vein Isolation Ablation versus a Matched Control Cohort.** *Heart Rhythm.* 2015;12(Supplement 5):S428.

Jarman JWE, March JL, Boo LM, Hunter TD **Comparison of Stroke and Heart Failure Survival in a Large UK Population with Atrial Fibrillation Treated with Pulmonary Vein Isolation Ablation versus a Matched Control Cohort.** *Heart Rhythm.* 2015;12(Supplement 5):S429.

Nazarian S, Reynolds MR, Ryan MP, Hunter TD, Wolff SD, Mollenkopf SA, Turakhia MP. **Estimating the Likelihood of MRI in Patients after ICD Implantation: A 10-Year Prediction Model.** *J Am Coll Cardiol.* 2015;65(10S):A1090.

Mallow P, Ryan M, Johnson M, Lim L, David G. **The Effect of the Choice of Contrast Media on Renal Failure Events in Angioplasty Procedures.** *Catheter Cardiovasc Interv.* 2015;85(Supplement S2):S37

Grossi EA, Moore M, Mallow PJ, Rizzo JA. **The Cost of an Operating Room Minute for Heart Valve Procedures.** *JHEOR.* 2015;2(2):170-80.

Hunter TD, Lip GY, Quiroz ME, Mollenkopf SA, Turakhia MP. **Cryptogenic Strokes and Second Ischemic Stroke Rates in Relation to the CHADS2 and CHA2DS2-VASc Risk Scores.** *Stroke.* 2015;46(Suppl 1):AWP189.

Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P, Schein JR. **International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.** *Curr Med Res Opin.* 2014;30(12):2437-2442.

Mallow PJ, Baniewicz J, Williams JM, Au-Yeung A. **A Cost Comparison Analysis of Medtronic's Stent Graft System to Competition for Endovascular Aneurysm Repair for Abdominal Aortic Aneurysms.** *Value Health.* 2014;17(7):A482.

Ladapo J, Turakhia MP, Landry-Wilson EM, Ryan MP, Irish W, Mollenkopf SA, Reynolds MR. **Remote Monitoring of Implantable Cardiovascular Devices is Associated with Reductions in Healthcare Utilization.** *Heart Rhythm* 2014;11(5):S1-S626.

Khaykin Y, Mallow PJ, Rizzo JA, Verma A, Chun L, Olesovsky S, Reynolds MR. **Cost-effectiveness of Catheter Ablation vs. Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective.** *Heart Rhythm* 2014;11(5):S1-S626.

Reynolds MR, David G, Gunnarsson C, March JL, Hao SC. **The Effects of Catheter Ablation Therapy on Medication Use and Expenditures in Patients with Atrial Fibrillation.** *JHEOR* 2014;2(1):15-28.

Oza SR, Hunter TD, Biviano AB, Dandamudi G, Herweg B, Patel AM, Pollak SJ, Wang H, Fishel RS. **Acute safety of an open-irrigated ablation catheter with 56-hole porous tip for radiofrequency ablation of paroxysmal atrial fibrillation: analysis from 2 observational registry studies.** *J Cardiovasc Electrophysiol* 2014;25(8):852-858.

Hunter TD, Quiroz ME, Gunnarsson C, Mollenkopf SA. **Characterization of Ischemic Stroke Patients and Second Stroke Rates by Risk Scores.** *Value Health.* 2014;17(3):A104.

Mallow PJ, Rowlandson I, Tasic D. **Outpatient Visits to the Cath Lab for Coronary Angiography Resulting in Minimal Action in the Short Term.** *Value Health.* 2014;17(3):A153.

Moore M, Mallow PJ, Rizzo JA. **The Variable Cost of an Operating Room Minute for Valvular Procedures.** *Value Health.* 2014;17(3):A112.

Mallow PJ, Rizzo JA. **Benefits of Managing Low-Density Lipoprotein Particles (LDL-P) in Conjunction with Low-Density Lipoprotein Cholesterol (LDL-C) for the Avoidance of Cardiovascular Disease Events: A Cost-Effectiveness Analysis.** Poster presented at *25th Annual National Forum on Quality Improvement in Health Care* December 8-11, 2013, Orlando, FL, USA.

Rodriguez R, Malaisrie SC, Mehall JR, Salemi A, Ailawadi G, Ryan W, Moore M, Gunnarsson C, Grossi EA. **Impact of surgical approach for aortic replacement on outcomes and cost: a multi-institution analysis of "real world" data.** Podium presentation at *The Society of Thoracic Surgeons (STS) 50th Annual Meeting* January 25-29, 2014, Orlando, FL, USA.

Phiri D, Mallow P, Rizzo JA. **The Cost Effectiveness of Hand Held Ultrasound Scanning for Abdominal Aortic Aneurysm in Older Males with a History of Smoking.** *JHEOR* 2013;1(2):96-107.

Rizzo JA, Mallow PJ, Waters HC, Pokrywka GS. **Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: a cost-effective analysis.** *J Clin Lipidol.* 2013;7(6):642-652.

Mallow PJ, Hsiao CW, Rizzo JA. **Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy for the treatment of atrial fibrillation in Canada.** *Value Health.* 2013;16(3):A289.

Reynolds MR, Hunter TD, Mollenkopf SA, Turakhia MP. **Identification of patients at high risk for subsequent development of atrial fibrillation or stroke using a claims database.** *Value Health.* 2013;16(3):A25.

Turakhia MP, Reynolds MR, Gunnarsson CL, Swain AL, Mollenkopf SA, Zweibel SL. **Healthcare resource utilization and expenditures associated with implantable cardioverter defibrillator shocks.** *Circ Cardiovasc Qual Outcomes.* 2013;6(3)Suppl:A3.

Gunnarsson C, Rizzo JA, Burton ML, Mollenkopf SA, Brill SL, Tsintzos S. **Cost Profile of Heart Failure Inpatient Admissions in the United States: Data from the Premier Hospital Database.** *Circ Cardiovasc Qual Outcomes.* 2013;6(3)Suppl:A66.

Turakhia MP, Hunter TD, Mollenkopf SA, Reynolds MR. **Rates of Atrial Fibrillation Diagnoses and Stroke Events by Combination of Risk Factors.** *Circ Cardiovasc Qual Outcomes.* 2013;6(3)Suppl:A239.

Reynolds MR, Hunter TD, Mollenkopf SA, Turakhia MP. **What risk factors cause both incident AF and stroke? An analysis of 1.8 M at-risk U.S. patients.** *Heart Rhythm.* 2013;10(5):S292.

Gunnarsson CL, Ryan MP, Turakhia MP, Wolff SD, Swain AL, Mollenkopf SA, Reynolds MR. **Radiology utilization in patients with and without pacemakers, evidence of a gap in care.** *Heart Rhythm.* 2013;10(5):S292-S293.

Reynolds MR, Hunter TD, Mollenkopf SA, Turakhia MP. **Extremely low use of ambulatory cardiac monitoring among American insured patients with arrhythmia-related symptoms at high risk of AF or stroke.** *J Am Coll Cardiol.* 2013;61(10_S):E301.

Reynolds MR, David G, Gunnarsson C, March J, Zhang M, Hao SC. **The effects of catheter ablation treatment on medication use and expenditures in patients with atrial fibrillation.** *Circulation.* 2012;126(21 Supplement):A16555.

Rizzo JA, Mallow P, Cirrincione A. **Forecasting the prevalence and economic burden of atrial fibrillation in selected countries, 2010-2025.** *Value Health.* 2012;15(7):A351.

Rizzo JA, Mallow P, Cirrincione A. **The economic burden of atrial fibrillation among elderly populations in selected developed countries.** *Value Health.* 2012;15(7):A352.

Rizzo JA, Mallow P, Cirrincione A. **Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy for the treatment of atrial fibrillation in the UK.** *Value Health.* 2012;15(7):A357.

Phiri D, Mallow P, Rizzo JA. **The cost effectiveness of hand held ultrasound scanning for AAA in elderly subjects with a history of smoking.** *Value Health.* 2012;15(7):A356.

Holt TA, Hunter TD, Gunnarsson C, Khan N, Cload P, Lip GY. **Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey.** *Br J Gen Pract.* 2012;62(603):e710-717.

Hao SC, Hunter TD, Gunnarsson C, March JL, White SA, Ladapo JA, Reynolds MR. **Acute safety outcomes in younger and older patients with atrial fibrillation treated with catheter ablation.** *J Interv Card Electrophysiol.* 2012;35(2):173-182.

Rizzo JA, Mallow P, Waters H, Cirrincione A. **Estimating the economic burden of atrial fibrillation in selected developing countries.** *Value Health.* 2012;15(4):A64.

Rizzo JA, Mallow P, Waters H, Cirrincione A. **The economic burden of atrial fibrillation among elderly populations in selected developed countries.** *Value Health.* 2012;15(4):A64.

Rizzo JA, Mallow P, Waters H, Cirrincione A. **Forecasting the prevalence and economic burden of atrial fibrillation in selected countries, 2010 – 2025.** *Value Health.* 2012;15(4):A64-A65.

Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, Zhang M, Hao SC. **Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a propensity matched analysis.** *Circ Cardiovasc Qual Outcomes.* 2012;5(2):171-181.

Marelli C, Gunnarsson C, Ross S, Haas S, Stroup DF, Cload P, Clopton P, DeMaria AN. **Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans.** *J Am Coll Cardiol.* 2011;58(5):530-537.

Ladapo JA, David G, Gunnarsson CL, Hao SC, White SA, March JL, Reynolds MR. **Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation.** *J Cardiovasc Electrophysiol.* 2012;23(1):1-8.

Hunter TD, Gunnarsson C, Bullano MF, de Vane PJ. **Is cardiovascular medication usage a marker for cardiovascular risk? Potential implication for smart-edit formulary management strategies.** *Value Health.* 2011;14(3):A50.

Ladapo JA, David G, Gunnarsson CL, Hao S, White S, March J, Zhang M, Reynolds M. **Reduction in healthcare utilization and expenditures in patients treated with catheter ablation for atrial fibrillation (AF) in the United States.** *Value Health.* 2011;14(3):A88.

Reynolds MR, Gunnarsson C, Hunter T, Ladapo J, March J, White SA, Zhang M, Hao SC. **Comparison of long term stroke or TIA risk between patients with atrial fibrillation who undergo radiofrequency catheter ablation vs. matched patients who have not had an ablation procedure.** *J Am Coll Cardiol.* 2011;57(14s1):E59.

Pilz G, Patel PA, Fell U, Ladapo JA, Rizzo JA, Fang H, Gunnarsson C, Heer T, Hoefling B. **Adenosine-stress cardiac magnetic resonance imaging in suspected coronary artery disease: a net cost analysis and reimbursement implications.** *Int J Cardiovasc Imaging.* 2011;27(1):113-121.

Cload P, Kallenbach L, Ross S, Haas S, Gunnarsson C. **Impact of a seminal study on practice patterns: statin use before and after the JUPITER study.** *Value Health.* 2010;13(3):A177.

Pilz G, Patel P, Fell U, Rizzo J, Fang H, Gunnarsson C, Graw M, Hoefling B. **Adenosine-stress cardiac magnetic resonance imaging in suspected coronary artery disease: a net cost analysis and reimbursement implications.** *J Cardio Magn Reson.* 2010;12(Suppl1):P295.

Budoff MJ, Karwasky R, Ahmadi N, Nasserian C, Pratt F, Stephens J, Chang WW, Flores FR, Rizzo JA, Gunnarsson CL, McKay CR. **Cost-effectiveness of multidetector computed tomography compared with myocardial perfusion imaging as gatekeeper to invasive coronary angiography in asymptomatic firefighters with positive treadmill tests.** *J Cardiovasc Comput Tomogr.* 2009;3(5):323-330.

Cload P, Marelli, C, Ross S, Zyczynski T, Haas S, Gunnarsson C. **Using electronic medical records (EMRS) to assess anticoagulation status according to stroke risk in patients with atrial fibrillation in ambulatory care settings.** *Value Health.* 2009;12(7):A320.

Pilz G, Patel P, Fell U, Rizzo R, Fang H, Gunnarsson C, Graw M, Hoefling B. **Adenosine-stress cardiac magnetic resonance imaging in suspected coronary artery disease: a net cost analysis & reimbursement implications.** *Value Health.* 2009;12(7):A344.

Circulatory System

Armstrong EJ, Ryan MP, Baker ER, Martinsen BJ, Kotlarz H, Gunnarsson C. **Risk of Major Amputation or Death among Patients with Critical Limb Ischemia Initially Treated with Endovascular Intervention, Surgical Bypass, Minor Amputation, or Conservative Management.** *J Med Econ.* 2017. Accepted for publication.

Rizzo JA, Chen J, Laurich C, Santos A, Martinsen, BJ, Ryan MP, Kotlarz H, Gunnarsson C. **Racial Disparities in PAD Related Amputation Rates among Native Americans and non-Hispanic Whites: an HCUP Analysis.** *J Health Care Poor Underserved.* 2017. Accepted for publication.

Gunnarsson, C, Chambers JW, Ryan MP, Baker ER, Kotlarz H, Martinsen BJ. **Atherectomy Utilization Shows Lower Odds of Adverse Events during Outpatient Percutaneous Coronary Interventions Compared to Angioplasty Alone.** *Value Health.* 2017;20(5):A267.

Gunnarsson, C, Lee MS, Ryan MP, Kotlarz H, Martinsen BJ. **Prevalence of Patients with Peripheral and Coronary Artery Disease.** *Value Health.* 2017;20(5):A267.

Palli SR, Rizzo JA, Martinsen BJ, Kotlarz H. **An Incremental Cost Analysis of Orbital Atherectomy Plus Angioplasty Compared to Angioplasty Alone for the Treatment of Critical Limb Ischemia.** *Value Health.* 2017;20(5):A266.

Gunnarsson C, Ryan MP, Boyes CW, Bolden PL, Baker ER, Kotlarz H, Martinsen BJ, Mustapha JA. **Risk of Major Amputation or Death among Peripheral Artery Disease Patients with Critical Limb Ischemia across Treatment Pathways.** *Value Health.* 2017;20(5):A266.

Gunnarsson C, Adams GL, Ryan MP, Kotlarz H, Martinsen BJ. **The Hospital Burden of Major Amputation Due to Peripheral Artery Disease in the United States.** *Value Health.* 2017;20(5):A266.

Mustapha JA, Fisher, Sr. BT, Rizzo JA, Chen J, Martinsen BJ, Kotlarz H, Ryan MP, Gunnarsson C. **Explaining Racial Disparities in Amputation Rates for the Treatment of Peripheral Artery Disease (PAD) using Decomposition Methods.** *J Racial Ethn Health Disparities.* 2016. Accepted for publication.

Zhao R, Gunnarsson C, Kotlarz H, Martinsen BJ, Palli S, Bell E, Rizzo JA. **An Incremental Cost Analysis of Orbital Atherectomy Plus Angioplasty Compared to Angioplasty Alone for the Treatment of Critical Limb Ischemia.** *Value Health.* 2016;19(3):A45.

Palli S, Gunnarsson C, Kotlarz H, Martinsen BJ, Zhao R, Rizzo JA. **Impact of a Limb Salvage Program on the Economic Burden of Amputation in the United States.** *Value Health.* 2016;19(3):A45.

Mustapha JA, Fisher, Sr. BT, Rizzo JA, Chen J, Martinsen BJ, Kotlarz H, Ryan MP, Gunnarsson C. **Racial Disparities in Amputation Rates for the Treatment of Peripheral Artery Disease using the Healthcare Cost and Utilization Project Database.** *Value Health.* 2016;19(3):A55-A56.

Rizzo JA, Chen J, Laurich C, Santos A, Martinsen BJ, Ryan MP, Kotlarz H, Gunnarsson C. **Racial Disparities in Amputation Rates among Native Americans with Peripheral Artery Disease: Analysis of the Healthcare Cost and Utilization Project Database.** *Value Health.* 2016;19(3):A55.

Rizzo JA, Chen J, Kotlarz H, Martinsen BJ, Ryan MP, Palli S, Gunnarsson C. **Racial Disparities in Amputation Rates for Patients with Peripheral Artery Disease: Long-Term Trends and Projections to 2020.** *Value Health.* 2016;19(3):A55.

Dermatology

Carter C, Schenkel B, Waters H, Haas S. **Real-world treatment patterns for the first year of ustekinumab therapy in patients with moderate to severe psoriasis.** *J Am Acad Dermatol.* 2013;68(4):AB209-Supplement 1.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. **The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey.** *J Dermatolog Treat.* 2012;23(4):240-254.

Lofland J, Rizzo J, Gunnarsson C, Chen J, Waters H. **The direct medical costs of psoriasis: evidence from United States national survey data.** *Value Health.* 2010;13(3):A206-A207.

Dysphagia

Plessinger D, Ryan MP, Gache LM, Baker ER, Gunnarsson C. **Dysphagia: A Retrospective Payer Database Analysis to Understand Patient Characteristics and Comorbid Profiles.** Poster accepted for presentation at the *Dysphagia Research Society (DRS) Annual Meeting*, March 2-4, 2017, Portland, OR, USA.

Plessinger D, Ryan MP, Gache LM, Gunnarsson C, Faught RE. **Estimating the Incremental Burden of Dysphagia in Epilepsy Patients: A Retrospective Payer Database Analysis.** Poster presented at the *2016 Annual Meeting of the American Epilepsy Society (AES)*, December 2–6, 2016, Houston, TX, USA.

Economic Model

Toney LK, Kim RD, Palli, SR. **The Economic Value of Hybrid Single-Photon Emission Computed Tomography with Computed Tomography Imaging in Pulmonary Embolism Diagnosis.** *Acad Emerg Med.* 2017. Accepted for publication.

Ammerman RT, Mallow PJ, Rizzo JA, Putnam FW, Van Ginkel JB. **Cost-effectiveness of In-Home Cognitive Behavioral Therapy for low-income depressed mothers participating in early childhood prevention programs.** *J Affect Disord.* 2017;208:475-482.

Rizzo JA, Rudmik L, Mallow PJ, Palli SR. **Budget impact analysis of bioabsorbable drug-eluting sinus implants following endoscopic sinus surgery.** *J Med Econ.* 2016;19(9):829-835.

Rudmik L, Mallow PJ, Palli S, Rizzo JA. **Budget Impact Analysis of Bioabsorbable Drug-Eluting Sinus Implants for Endoscopic Sinus Surgery.** *Value Health.* 2015;18(7):A368.

Ammerman RT, Chen J, Mallow PJ, Rizzo JA, Folger AT, Van Ginkel JB. **Annual direct health care expenditures and employee absenteeism costs in high-risk, low-income mothers with major depression.** *J Affect Disord.* 2015;190:386-394.

Ammerman RT, Chen J, Mallow PJ, Rizzo JA, Folger AT, Van Ginkel JB. **Annual Direct Health Care Expenditures and Employee Absenteeism Costs in High-Risk, Low-Income Mothers with Major Depression.** Oral presentation at the *Perinatal Mental Health Conference*, November 4-6, 2015, Chicago, IL, USA.

Mallow PJ, Irish W, Rizzo JA. **Pricing, Economics, Reimbursement, Market Share (PERMS) Strategy: An Interactive Holistic Approach for Rare Diseases.** Podium presentation at *Drug Information Association (DIA) 50th Annual Meeting*, June 15-19, 2014, San Diego, CA, USA.

Mallow PJ, Rizzo JA, Irish W, Okere CE. **A Comprehensive Economic and Pricing Modeling Framework for Understanding Orphan Drug Development.** *Value Health.* 2014;17(3):A205.

Endocrine Disorders/Obesity

Heidrich N, Palli SR. **The Short- and Long-Term Economic Impact of Bariatric Surgery Coverage for a Payer.** Poster accepted for presentation at *ObesityWeek 2017* October 29-November 2, 2017, Washington, DC, USA.

Gunnarsson C, Ryan MP, Marelli C, Baker ER, Stewart PM, Johannsson G, Biller BMK. **Health Care Burden in Patients With Adrenal Insufficiency.** *J Endocr Soc.* 2017;1(5):512:523.

Stewart PM, Biller BM, Marelli C, Gunnarsson C, Ryan MP, Johannsson G. **Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency.** *J Clin Endocrinol Metab.* 2016;101(12):4843-4850.

Stewart PM, Biller BMK, Marelli C, Gunnarsson C, Ryan M, Johannsson G. **Increased morbidity and hospital admissions in patients with adrenal insufficiency.** *Endocrine Abstracts.* 2016;41:GP16.

Ghosh SK, Ryan MP, Gache LM, Roy S, Fegelman E. **Differences in Clinical Outcomes and Costs Associated with the Use of Staple Line Buttress In Bariatric Surgery.** *Value Health.* 2016;19(3):A246.

Hatoum IJ, Blackstone R, Hunter TD, Francis DM, Steinbuch M, Harris JL, Kaplan LM. **Clinical Factors Associated With Remission of Obesity-Related Comorbidities After Bariatric Surgery.** *JAMA Surg.* 2016;151(2):130-137.

Boscoe A, Ryan M, Iloeje U, Kincaid J, Irish W, Laurence J. **Early Access to Eculizumab Improves Clinical Outcomes and Reduces In-Hospital Resource Use in Patients with Atypical Hemolytic Uremic Syndrome (aHUS).** Poster presented at *American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition*, December 6-10, 2015, New Orleans, LA, USA.

Irish W, Boscoe A, Ryan MP, Iloeje U, Gunnarsson C, Marks W. **Economic Burden of Antibody Mediated Rejection Following Kidney Transplantation: Comparative Analysis using the Premier Hospital Database.** *Value Health.* 2015;18(3):A187.

Stewart P, Biller BMK, Marelli C, Gunnarsson C, Ryan M, Johannsson G. **Defining and exploring the excessive healthcare burden of Adrenal Insufficiency.** *Endocrine Abstracts.* 2015;37:GP.01.02.

David G, Gill M, Gunnarsson C, Shafiroff J, Edelman S. **Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetes.** *Am J Manag Care.* 2014;20(11):e490-e497.

Benoit SC, Hunter TD, Francis DM, De La Cruz-Munoz N. **Use of Bariatric Outcomes Longitudinal Database (BOLD) to Study Variability in Patient Success after Bariatric Surgery.** *Obes Surg* 2014;24(6):936-43.

Holt TA, Gunnarsson CL, Cload PA, Ross SD. **Identification of undiagnosed diabetes and quality of diabetes care in the United States: cross-sectional study of 11.5 million primary care electronic records.** *CMAJ Open* 2014;2(4):E248-255.

Holt TA, Gunnarsson C, Cload P, Ross S. **Identification of undiagnosed diabetes and quality of diabetes care in the US: Retrospective observational cohort analysis using electronic records.** *Prim Health Care Res Dev.* 2013;14(S1):1-106.

Benoit SC, Francis DM, Hunter TD. **Analysis of bariatric outcomes longitudinal database (BOLD) to predict percent BMI loss after bariatric surgery.** *Value Health.* 2012;15(4):A73-A74.

Hatoum IJ, Hunter TD, Francis DM, Steinbuch M, Kaplan LM. **Identification of bariatric surgical procedures, comorbidities and adverse events in payor data.** *Value Health.* 2012;15(4):A80.

David G, Shafiroff J, Saulnier A, Gunnarsson C. **Multiple daily injection therapy (MDI) versus durable insulin pump therapy in Type II diabetics: a breakeven analysis.** *Value Health.* 2012;15(4):A65.

Benoit S, Hunter TD, Steinbuch M, Fegelman E, Francis D, Seeley R. **Using electronic medical records to identify potential predictors for bariatric surgery success.** *Value Health.* 2011;14(3):A86.

Crawford AG, Cote C, Couto J, Daskiran M, Gunnarsson C, Haas K, Haas S, Nigam SC, Schuette R. **Prevalence of obesity, type II diabetes mellitus, hyperlipidemia, and hypertension in the United States: findings from the GE Centricity Electronic Medical Record database.** *Popul Health Manag.* 2010;13(3):151-161.

Cload P, Zyczynski T, Ross S, Haas S, Gunnarsson C. **Underuse of BMD measurements and bisphosphonate treatment in women over age 50 with osteoporosis in a nationally-representative EMR database.** *Value Health.* 2010;13(3):A131.

Marelli C, Cload P, Zyczynski T, Ross S, Gunnarsson C, Haas S. **Using electronic medical records to identify undiagnosed diabetes mellitus in primary care practices.** *Value Health.* 2009;12(7):A234.

Cawley J, Rizzo J, Gunnarsson C, Haas K. **The health care costs effects of diabetes among obese and morbidly obese adults in the United States.** *Value Health.* 2008;11(3):A156.

Cawley J, Rizzo J, Haas K (For S² Statistical Solutions, Inc.). **The association of diabetes with job absenteeism costs among obese and morbidly obese workers.** *J Occup Environ Med.* 2008;50(5):527-534.

Cawley J, Rizzo J, Haas K (For S² Statistical Solutions, Inc). **Occupation-specific absenteeism costs associated with obesity and morbid obesity.** *J Occup Environ Med.* 2007;48(12):1317-1324.

Gastrointestinal Disease

David G, Gunnarsson C, Lofland JH. **Variations in Care: A Retrospective Database Analysis of Healthcare Utilization Patterns for Patients with Inflammatory Bowel Disease.** *J Med Econ.* 2015;18(2):137-144.

Ghosh SK, Roy S, Ryan MP, Gunnarsson C, Yoo AC. **Incremental Burden of Anastomotic Leaks in Colorectal Surgeries.** *Value Health.* 2014;17(3):A78.

David G, Mallow PJ, Cantu H, Lofland J. **Effects of Patient Annual Adherence of Biologics on Healthcare Resource Utilization for Patients with Inflammatory Bowel Disease.** *Gastroenterology.* 2014;146(5):S-434.

Mallow P, Rizzo J, Gathany T, Lofland J. **Cost per Clinical Response, Clinical Remission, and Mucosal Healing of Adalimumab, Golimumab, and Infliximab Among Patients with Ulcerative Colitis (UC).** Poster presented at *Crohn's & Colitis Foundation's Clinical & Research Conference* December 12-14, 2013, Hollywood, FL, USA.

Mallow P, Rizzo J, Gathany T, Lofland J. **Cost per Clinical Response, Clinical Remission, and Mucosal Healing of Golimumab Among Patients with Ulcerative Colitis: Results from PURSUIT-Maintenance.** Poster presented at *Crohn's & Colitis Foundation's Clinical & Research Conference* December 12-14, 2013, Hollywood, FL, USA.

David G, Gunnarsson CL, Lofland J, Goodney P, Siegel CA. **Geographic Variation in Care of Patients with Inflammatory Bowel Disease Suggests Unequal Quality of Care in the United States.** *Gastroenterology.* 2013 144(5)Supplement 1:S647.

Mallow PJ, Rizzo JA, Queener MK, Gathany TA, Lofland J. **Cost per clinical remission and clinical response of adalimumab, golimumab and infliximab in the treatment of patients with ulcerative colitis: an induction analysis.** *Am J Gastroenterol.* 2013;108(Supplement 1s):S515-S516.

Mallow PJ, Rizzo JA, Queener MK, Gathany TA, Lofland J. **Comparative efficacy of adalimumab, golimumab and infliximab in the treatment of patients with ulcerative colitis: an induction analysis.** *Am J Gastroenterol.* 2013;108(Supplement 1s):S514.

Lofland JH, Mallow P, Rizzo J. **Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis.** *J Med Econ.* 2013;16(4):461-467.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. **The employee absenteeism costs of inflammatory bowel disease: evidence from US national survey data.** *J Occup Environ Med.* 2013;55(4):393-401.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. **Direct healthcare insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.** *Dig Dis Sci.* 2012;57(12):3080-3091.

Feagan B, Gunnarsson C, Mallow P, Rizzo J, Lofland J. **Cost-per-responder analysis of infliximab compared to adalimumab among individuals with moderate to severe ulcerative colitis.** *Can J Gastroenterol.* 2012;26:SupplSA.

Lofland J, Gunnarsson C, Mallow P, Rizzo J, Feagan B. **Cost-per-responder analysis of infliximab compared to adalimumab among individuals with moderate to severe ulcerative colitis.** *Am J Gastroenterol.* 2011;106:Suppl2:S418.

Inadomi J, Gunnarsson C, Rizzo JA, Fang H. **Projected increased growth rate of anesthesia professional-delivered sedation for colonoscopy and EGD in the United States: 2009:2015.** *Gastrointest Endosc.* 2010;72(3):580-586.

Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J, Waters H. **The direct costs of inflammatory bowel disease: evidence from United States national survey data.** *Value Health.* 2010;13(3):A206.

Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J, Waters H. **The indirect costs of inflammatory bowel disease: evidence from United States national survey data.** *Value Health.* 2010;13(3):A207.

Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J, Waters H. **The direct costs of inflammatory bowel disease: evidence from United States national survey data.** *Gastroenterology.* 2010;138(5)Suppl 1:S-217.

Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J, Waters H. **The indirect costs of inflammatory bowel disease: evidence from United States national survey data.** *Gastroenterology.* 2010;138(5)Suppl 1:S-217.

Inadomi J, Gunnarsson C, Rizzo JA, Fang H. **The predicted cost of anesthesia professionally-delivered sedation for colonoscopy and EGD in the United States and the impact of computer-assisted personalized sedation.** Poster presented at the *7th Annual World Health Care Congress* April 12-14, 2010, National Harbor, MD, USA.

Hepatitis

Irish W, Saynisch P, Mallow PJ, Fallon L, Gunnarsson C. **Using the Medicare claims database to understand the Economic burden of Liver disease: a case study in Hepatic Encephalopathy.** *Value Health.* 2015;18(3):A226.

Tandon N, David G, Ryan M, Gunnarsson C. **Pharmacy cost of managing anemia among patients receiving chronic hepatitis C therapy.** *Med Decis Making* 2014;34(2): E95.

Tandon N, Gunnarsson C, Prabhakar A. **Patient characteristics and utilization of protease inhibitors in Hepatitis C (HCV) patients in a large payer database.** *J Hepatol* 2013;58Supplement 1:S205-S206

Tandon N, Gunnarsson C, Prabhakar A. **Patient characteristics and drug utilization among Hepatitis C (HCV) patients in a large payer database.** *Gastroenterology.* 2013;144(5)Supplement 1:S-988-S-989.

Tandon N, Gunnarsson C, Prabhakar A. **Patient characteristics and drug utilization among Hepatitis C (HCV) patients in a large payer database.** *Value Health.* 2013;16(3):A211.

Hospitals and Institutions

Rajagopalan K, Robinson SB, Ernst FR, Hunter T, Johnson BH, Bollu VK. **Length of Stay and Costs of COPD: Analysis of Hospitalized Patients Treated With Arformoterol or Nebulized Short- Acting Beta₂-Agonists.** *J Clin Pathways.* 2017;4(2):37-43.

David G, Mallow PJ, Wang QC, Vartanian Fritz S, Chawla R, Nigam S. **Does Real Time Insurance Claims-Based Analysis Impacts Population Health?** Abstract presented as part of an oral presentation entitled “Using Big Data to Improve Population Health” at the conference of the *America Society of Health Economists (ASHEcon)*, June 12-15, 2016, University of Pennsylvania, Philadelphia, PA, USA.

David G, Saynisch PA, Smith-McLallen A. **The Inner Workings of the Patient-Center Medical Home Model.** Abstract presented as part of an oral presentation entitled “The Economics of Patient-Centered Medical Homes” at the conference of the *America Society of Health Economists (ASHEcon)*, June 12-15, 2016, University of Pennsylvania, Philadelphia, PA, USA.

David G, Lim S, Gunnarsson C, Kocharian R, Roy S. **Similar patient outcomes yet different hospital costs between flowable hemostatic agents.** *J Med Econ.* 2015;18(9):735-745.

Patel PA, Mallow PJ, Vassar M, Rizzo JA, Pandya BJ, Kruzikas DT. **Traumatic Brain Injury: Patient Characteristics, Hospital Costs and Trends over Time.** *JHEOR*. 2014;2(2):108-118.

David G, Gunnarsson C, Saynisch PA, Chawla R, Nigam S. **The Inner Workings of the Patient-Center Medical Home Model.** Presented at the *26th Annual Health Economics Conference (AHEC)*, October 23-24, 2015, University of Georgia, Athens, GA, USA.

David G, Gunnarsson C, Saynisch PA, Chawla R, Nigam S. **Do patient-centered medical homes reduce emergency department visits?** *Health Serv Res*. 2015;50(2):418-439.

David G, Lim S, Gunnarsson C, Delatore P, Kocharian R. **The effect of the choice of gelatin hemostatic matrix on hospital cost and clinical outcomes in spinal procedures.** Poster presented at the *30th Annual Meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves* March 5-8, 2014, Orlando, FL USA.

Smith-McLallen A, Helmchen L, Cruz S, Chawla, R, Gunnarsson C, Nigam S. **Impact of Rewarding Relative Performance on Health Care Quality in a Primary Care Setting.** *Med Decis Making* 2014;34(2):E91.

David G, Gunnarsson C, Saynisch PA, Chawla R, Nigam S. **Do Patient-Centered Medical Homes Reduce Emergency Department Visits?** Presented at the *11th Annual Southeastern Health Economics Study Group Conference* October 25-26, 2013, Baltimore, MD, USA.

David G, Gunnarsson C, Saynisch PA, Chawla R, Nigam S. **Do Patient-Centered Medical Homes Reduce Emergency Department Visits?** Presented at the Department of Epidemiology Seminar. *Columbia University Mailman School of Public Health* December 6, 2013, New York, NY, USA.

Mallow PJ, Pandya B, Horblyuk R, Kaplan HS. **Prevalence and cost of hospital medical errors in the general and elderly United States populations.** *J Med Econ*. 2013;16(12):1367-1378.

Mitchell A, Rohde R, Mallow P, Buskirk D. **Economic burden of methicillin-resistant *Staphylococcus aureus*, *Clostridium difficile* and vancomycin-resistant *Enterococci* in hospitals.** *Antimicrob Resist Infect Control* 2013;2(Suppl 1):P67.

Tasic D, Baker ER, Mallow P, Turgeon K. **A systematic review on the application of electrocardiographs transmitted prior to hospital arrival on door to treatment times.** *Value Health*. 2013;16(3):A294.

Rizzo JA, Gunnarsson C, Burton ML, Mollenkopf SA, Brill SL, Tsintzos S. **The cost to US hospitals for Heart Failure (HF) inpatient admissions across DRGs: a retrospective multi-center study.** *Value Health*. 2013;16(3):A282.

David G, Gunnarsson CL, Waters H, Horblyuk R, Kaplan HS. **Economic Measurement of Medical Errors Using a Hospital Claims Database.** *Value Health.* 2013;16(2):305-310.

Chawla R, Colombo C, David G, Gunnarsson C, Snyder R, Nigam S. **Patient-centered medical homes reduce inpatient admissions and expenditures for chronic members.** Poster presented at the *24th Annual National Forum on Quality Improvement in Health Care* December 9-12, 2012, Orlando, FL, USA.

Horblyuk R, Kaplan HS, Lee DW, David G, Gunnarsson C. **Applying actuarial methodology to hospital data for estimation of medical errors.** *Value Health.* 2012;15(4):A29.

Kaplan HS, Horblyuk R, Lee DW, David G, Gunnarsson C. **Measurement of medical errors using a hospital claims database.** Poster presented at the *23rd Annual National Forum on Quality Improvement in Health Care* December 4-7, 2011, Orlando, FL, USA.

Patel PA, Gunnarsson C. **A passive monitoring system in assisted living facilities: 12-month comparative study.** *Phys Occup Ther Geriatr.* 2012;30(1):45–52.

Patel PA, Gunnarsson CL. **Use of a passive monitoring system in assisted living facilities – a 12 month comparative study.** Poster presented at the *ASA 2011 Aging in America Conference* April 26–30, 2011, San Francisco, CA, USA.

Medical Devices and Minimally Invasive Procedures

Hunter TD, DeConde AS, Maines RP. **Disease-Related Cost Burden in Patients Undergoing Sinus Surgery for Chronic Rhinosinusitis: A Claims-Based Analysis.** Poster accepted for presentation at *ISPOR 20th Annual European Congress*, November 4-8, 2017, Glasgow, Scotland.

Falowski S, Safriel Y, Ryan MP, Hargens L. **The Rate of Magnetic Resonance Imaging in Patients with Deep Brain Stimulation.** *Stereotact Funct Neurosurg.* 2016;94(3):147-153.

Sohail MR, Eby EL, Ryan MP, Wright LA, Greenspon AJ. **The Rate of CIED Infection by Severity: Evidence from a Large US Payer Database.** *Open Forum Infect Dis.* 2015;2(suppl 1):S144-S145.

Gunnarsson C, Barnett G, Walleser Autiero S, Hinnenthal J, Safriel Y, Ryan M, Conroy MJ. **Estimating the need for MRI conditionally safe deep brain stimulation systems in Parkinson's disease patients: a European perspective.** *Insights Imaging.* 2015;6(1 Supplement):S179.

Desai MJ, Hargens LM, Breitenfeldt MD, Doth AH, Ryan MP, Gunnarsson C, Safriel Y. **The rate of magnetic resonance imaging in patients with spinal cord stimulation.** *Spine (Phila Pa 1976)*. 2015;40(9):E531-E537.

Hatheway JA, Caraway D, David G, Gunnarsson C, Hinnenthal J, Ernst AR, Saulino M. **Systemic opioid elimination after implantation of an intrathecal drug delivery system significantly reduced health-care expenditures.** *Neuromodulation*. 2015;18(3):207-213.

Boehme J, McKinley S, Michael Brunt L, Hunter TD, Jones DB, Scott DJ, Schwaizberg SD. **Patient comorbidities increase postoperative resource utilization after laparoscopic and open cholecystectomy.** *Surg Endosc*. 2016;30(6):2217-2230.

Boehme J, McKinley S, Michael Brunt L, Hunter TD, Jones DB, Scott DJ, Schwaizberg SD. **Patient comorbidities increase postoperative resource utilization after laparoscopic and open cholecystectomy.** *Surg Endosc*. 2015;29(1 Supplement):314-354.

Falowski S, Safriel Y, Ryan M, Hargens L. **The Need For Magnetic Resonance (MR) Imaging In The United States (US) Deep Brain Stimulation (DBS) Population.** *Neuromodulation*. 2015;18(2):e13-e106.

Hatheway J, Caraway D, David G, Gunnarsson C, Hinnenthal J, Ernst A, Saulino M. **Systemic Opioid Elimination after Implantation of an Intrathecal Drug Delivery System Significantly Reduced Healthcare Expenditures.** *Neuromodulation*. 2015;18(2):e13-e106.

Boehme J, McKinley SK, Brunt LM, Hunter TD, Jones DB, Scott DJ, Schwaizberg SD. **Patient Comorbidities Increase Postoperative Resource Utilization After Laparoscopic and Open Cholecystectomy.** Poster presented at the *Massachusetts Medical Society (MMS) Ninth Annual Research Poster Symposium for Residents, Fellows, and Medical Students* December 5, 2014, Waltham, MA, USA.

Rodriguez E, Malaisrie SC, Mehall JR, Moore M, Salemi A, Ailawadi A, Gunnarsson C, Ward AF, Grossi EA; Economic Workgroup on Valvular Surgery. **Right anterior thoracotomy aortic valve replacement is associated with less cost than sternotomy-based approaches: a multi-institution analysis of "real world" data.** *J Med Econ*. 2014;17(12):846-52.

Schwaizberg SD, Scott DJ, Jones DB, McKinley SK, Castrillion J, Hunter TD, Michael Brunt L. **Threefold increased bile duct injury rate is associated with less surgeon experience in an insurance claims database: More rigorous training in biliary surgery may be needed.** *Surg Endosc*. 2014;28(11):3068-3073.

Caraway D, Hatheway J, David G, Gunnarsson C, Hinnenthal J, Spencer R, Saulino M. **Discontinuation of Systemic Opioid Usage After Implantation of Intrathecal Drug Delivery System reduces Expenditures.** *Pain Physician*. 2014;17(3):E431.

Swanson S, Miller D, McKenna R, Meyers B, Marshall MB, Ghosh SK, Fegelman E, Roy S, Ryan M, Gunnarsson C, Howington JA. **Economic Burden of Prolonged Air Leak after Lung Resection: Open Versus Video-Assisted Thoracoscopic Surgery (VATS).** *Value Health.* 2014;17(3):A80.

Schwaitzberg SD, Scott DJ, Jones DB, McKinley SK, Castrillion J, Hunter T, Brunt LM. **Bile Duct Injury Prevention Requires a New National Training Paradigm Despite Successful Deployment of FLS.** *Surg Endosc.* 2014;28(1) Supplement:311-445.

Desai MJ, Ryan M, Hargens LM, Doth AH. **Estimating the need for Magnetic Resonance Imaging (MRI) in patients with Spinal Cord Stimulation (SCS).** *Pain Medicine.* 2014;15(3):485–537.

Grossi EA, Goldman S, Wolfe JA, Mehall JR, Smith JM, Ailawadi G, Salemi A, Moore M, Ward AF, Gunnarsson CL. **Mini-thoracotomy for Mitral Valve Repair Improves Inpatient and Post Discharge Economic Savings.** Poster presented at *American Association for Thoracic Surgery's (AATS) 94th Annual Meeting* April 26-30, 2014, Toronto, ON, Canada.

Grossi EA, Goldman S, Wolfe JA, Mehall J, Smith JM, Ailawadi G, Salemi A, Moore M, Ward A, Gunnarsson C; Economic Workgroup on Valvular Surgery. **Minithoracotomy for mitral valve repair improves inpatient and postdischarge economic savings.** *J Thorac Cardiovasc Surg.* 2014;148(6):2818-2822.e1-3.

Mallow PJ, DeRamus S, Baker ER, McKenna M. **Impact of Computer-Assisted Personalized Sedation on Components of Colonoscopy Procedure Time.** Poster presented at *25th Annual National Forum on Quality Improvement in Health Care*, December 8-11, 2013, Orlando, FL, USA.

Davis BR, Yoo AC, Moore M, Gunnarsson C. **Robotic-assisted versus laparoscopic colectomy: cost and clinical outcomes.** *JSLs.* 2014;18(2):211-224.

Desai MJ, Ryan M, Hargens L, Doth A. **Estimating the need for Magnetic Resonance Imaging (MRI) in patients with Spinal Cord Stimulation (SCS).** *Neuromodulation.* 2015;18(2):e13-e106.

Swanson SJ, Miller DL, McKenna RJ Jr, Howington J, Marshall MB, Yoo AC, Moore M, Gunnarsson CL, Meyers, BF. **Comparing robot-assisted thoracic surgical lobectomy with conventional video-assisted thoracic surgical lobectomy and wedge resection: Results from a multihospital database (Premier).** *J Thorac Cardiovasc Surg.* 2014;147(3):929-937.

Chekan E, Moore M, Hunter TD, Gunnarsson C. **Costs and clinical outcomes of conventional single port and mini-laparoscopic cholecystectomy.** *JSLs.* 2013;17(1):30-45.

David G, Gunnarsson CL, Moore M, Howington J, Miller DL, Maddaus MA, McKenna RJ Jr, Meyers BF, Swanson SJ. **Surgeons' volume-outcome relationship for lobectomies and wedge resections for cancer using video-assisted thoracoscopic techniques.** *Minim Invasive Surg.* 2012;2012:760292.

Davis BR, Yoo AC, Moore M, Haas S, Gunnarsson C. **Comparing robot-assisted to conventional laparoscopic colectomy: impact on cost and clinical outcomes.** *Value Health.* 2012;15(4):A75.

Moore M, Yoo AC, Devadason G, Haas S, Gunnarsson C. **Comparing robot-assisted to conventional video-assisted thoracic surgical (VATS) lobectomy and wedge resection: results from a multi-hospital (Premier) database.** *Value Health.* 2012;15(4):A75.

Chekan E, Moore M, Hunter T, Gunnarsson C. **Laparoscopic cholecystectomy: a retrospective analysis of hospital costs and patient outcomes when comparing traditional laparoscopic to single port and micro-laparoscopic surgical approaches.** *Surg Endosc.* 2012;26(1) Supplement:249-430.

Howington JA, Gunnarsson CL, Maddaus MA, McKenna RJ, Meyers BF, Miller D, Moore M, Rizzo JA, Swanson S. **In-hospital clinical and economic consequences of pulmonary wedge resections for cancer using video-assisted thoracoscopic techniques vs traditional open resections: a retrospective database analysis.** *Chest.* 2012;141(2):429-435.

Patel PA, Ernst FR, Gunnarsson CL. **Evaluation of hospital complications and costs associated with using ultrasound guidance during abdominal paracentesis procedures.** *J Med Econ.* 2012;15(1);1-7.

Patel PA, Ernst FR, Gunnarsson CL. **Ultrasonography guidance reduces complications and costs associated with thoracentesis procedures.** *J Clin Ultrasound.* 2012;40(3):135-141.

Mallow P, Gunnarsson C, Rizzo JA. **Cost savings through the prevention of blood spray exposure during an umbilical cord transection.** Poster presented at the *AOHP 2011 National Conference*, September 28-October 1, 2011, Minneapolis, MN, USA.

Swanson SJ, Meyers BF, Gunnarsson CL, Moore M, Howington JA, Maddaus MA, McKenna RJ, Miller DL. **Video-assisted thoracoscopic lobectomy is less costly and morbid than open lobectomy: a retrospective multiinstitutional database analysis.** *Ann Thorac Surg.* 2012;93(4):1027-1032.

David G, Gunnarsson CL, Moore M, Howington J, Miller D, Maddaus M, McKenna R, Meyers B, Swanson S. **Surgeon's volume-outcomes relationship for lobectomies and wedge resections for cancer using video-assisted thoracoscopic techniques.** *Value Health.* 2011;14(3):A86-A87.

Swanson SJ, Howington JA, Meyers BF, Miller DL, Maddaus MA, McKenna RJ. **Video-assisted thoracoscopic (VATS) lobectomy is less costly and morbid than open lobectomy: a retrospective multi-institution database analysis.** Poster presented at the *STS 47th Annual Meeting* January 31-February 2, 2011, San Diego, CA, USA.

Pasic RP, Rizzo JA, Fang H, Ross S, Moore M, Gunnarsson C. **Comparing robot-assisted with conventional laparoscopic hysterectomy: impact on cost and clinical outcomes.** *J Minim Invasive Gynecol.* 2010;17(6):730-738.

Howington, JA, Gunnarsson C, Maddaus MA, McKenna RJ, Miller D, Myers BF, Moore M, Swanson S. **Clinical and economic consequences of pulmonary wedge resections for cancer using video-assisted thoracoscopic techniques vs. traditional open resections: a retrospective database analysis.** *Chest.* 2010;138(4)Supp 660A.

Patel PA, Ernst FR, Gunnarsson CL. **Evaluation of hospital complications and costs associated with thoracentesis with or without ultrasound guidance.** *Chest.* 2010;138(4)Supp 333A.

Gunnarsson CL, Patel PA, Ernst FR. **Evaluation of hospital complications and costs associated with ultrasound guided paracentesis.** *Am J Gastroenterol* 2010;105 Suppl 1:S393.

Nasciben V, Rupprecht F, Moore M, Gunnarsson C. **The economic impact of contour versus hand sewn suture and other mechanical staples in low anterior resections in colon rectal cancer surgery: Interim results using real world data from Premier's hospital database.** *Value Health.* 2010;13(3):A49.

Fullum TM, Ladapo JA, Borah BJ, Gunnarsson CL. **Comparison of the clinical and economic outcomes between open and minimally invasive appendectomy and colectomy: evidence from a large commercial payer database.** *Surg Endosc.* 2010;24(4):845–853.

Warren L, Ladapo JA, Borah BJ, Gunnarsson CL. **Open abdominal versus laparoscopic and vaginal hysterectomy: analysis of a large United States payer measuring quality and cost of care.** *J Minim Invasive Gynecol.* 2009;16(5):581-588.

Gunnarsson C, Rizzo JA, Hochheiser L. **The effects of laparoscopic surgery and nosocomial infections on the cost of care: evidence from three common surgical procedures.** *Value Health.* 2009;12(1):47-54.

Moore M, Hochheiser L, Gunnarsson C, Ladapo J, Borah B. **Regional disparities and economic outcomes associated with minimally invasive and conventional surgeries of the chest, abdomen, and pelvis.** *Value Health.* 2009;12(3):A63

Warren L, Ladapo JA, Borah B, Gunnarsson C. **Abdominal vs. laparoscopic and vaginal hysterectomy: analysis of a large US payer measuring quality & cost of care.** Podium presentation at *Global Congress of Minimally Invasive Gynecology (AAGL) 38th Annual Meeting* November 15-19, 2009, Orlando, FL, USA.

Brill A, Ghosh K, Gunnarsson C, Rizzo J, Fullum T, Maxey C, Brossette S. **The effects of laparoscopic cholecystectomy, hysterectomy, and appendectomy on nosocomial infection risks.** *Surg Endosc.* 2008;22(4):1112-1118.

Rizzo J, Gunnarsson C, Hochheiser L, Moore M. **The effects of laparoscopic surgery and nosocomial infections on the cost of care: evidence from three surgical procedures.** *Value Health.* 2007;10(6):A474

Orthopedics

Chen J, Rizzo JA, Parasuraman S, Gunnarsson C. **Racial disparities in receiving total hip/knee replacement surgery: the effect of hospital admission sources.** *J Health Care Poor Underserved.* 2013;24(1):135-151.

Kotlarz H, Chen J, Rizzo J, Gunnarsson C. **Racial and ethnic disparities in total knee replacement surgery.** *Value Health.* 2010;13(3):A132.

Kotlarz H, Chen J, Rizzo J, Gunnarsson C. **Racial and ethnic disparities in total hip replacement surgery.** *Value Health.* 2010;13(3):A132.

Peoples S, Rizzo J, Kotlarz H. **Health economics model for total hip arthroplasty: cost savings achieved by newer technology.** *Value Health.* 2008;11(3):A256-A257.

Osteoarthritis

Kotlarz H, Gunnarsson C, Fang H, Rizzo J. **Osteoarthritis and absenteeism costs: evidence from U.S. National survey data.** *J Occup Environ Med.* 2010;52(3):263-268. Article accepted for Continuing Medical Education (CME).

Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. **Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data.** *Arthritis Rheum.* 2009;60(12):3546-3553.

Kotlarz H, Gunnarsson C, Rizzo J. **Osteoarthritis and job absenteeism costs: Evidence from U.S. national survey data.** *Value Health.* 2008;11(6):A546.

Kotlarz H, Gunnarsson C, Rizzo J. **The direct health care costs of osteoarthritis: evidence from U.S. national survey data.** *Value Health.* 2008;11(6):A546.

Rare Diseases

Bilder DA, Noel JK, Baker ER, Irish W, Chen Y, Merilainen MJ, Prasad S, Winslow BJ. **Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults with Phenylketonuria.** *Dev Neuropsychol.* 2016 Epub ahead of print.

Bilder DA, Noel JK, Baker E, Irish W, Winslow BJ, Jain R, Chen Y, Merilainen MJ, Prasad S. **A systematic review (SR) and meta-analysis (MA) to assess the prevalence of neuropsychiatric symptoms in adults with phenylketonuria (PKU).** *J Inherit Metab Dis.* 2014;37(Suppl 1):S178.

Bilder DA, Noel JK, Baker ER, Irish W, Winslow BJ, Jain R, Chen Y, Merilainen MJ, Prasad S. **A systematic review (SR) and meta-analysis (MA) to assess blood phenylalanine (Phe) levels in adults with phenylketonuria (PKU).** *J Inherit Metab Dis.* 2014;37(Suppl 1):S178.

Bilder DA, Noel JK, Baker ER, Irish W, Winslow BJ, Jain R, Chen Y, Prasad S, Merilainen MJ. **A systematic review (SR) of the effectiveness of reducing blood phenylalanine (Phe) levels in adults with phenylketonuria (PKU) on neuropsychiatric symptoms.** *J Inherit Metab Dis.* 2014;37(Suppl 1):S62.

Research Methods

David G, Johnson M, Lim L, Mallow PJ. **Selection of Statistical Approach in Understanding the Role of Contrast Media in Inpatient Interventional Cardiovascular Procedures.** *Value Health.* 2015;18(7):A682-A683.

Nakagawa JA, Irish W, Ryan M, Womeldorff J, Roberds SL. **Symptoms of tuberous sclerosis complex: comparison of TSC1 versus TSC2 gene mutation.** Poster presented at *2015 International Research Conference on Tuberous Sclerosis Complex: from Treatment to Prevention.* September 10-12, 2015, Windsor, UK.

Sietsema W, Wekselman K. **“Agency Meetings with the US Food and Drug Administration.”** *Regulatory Focus.* April 2015. Regulatory Affairs Professionals Society.

Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. **Adjusting for comorbidities in cost of illness studies.** *J Med Econ.* 2015;18(1):12-28.

Cload P, Mallow P, Mako J, Gunnarsson C. **Data visualization for business intelligence: assessing an online tool used for benchmarking hospital procedure costs to reimbursement in cardiac catheterization and electrophysiology procedures.** *Value Health.* 2011;14(7):A254.

Crawford A, Cote C, Couto J, Daskiran M, Gunnarsson C, Haas K, Haas S, Nigam S, Schuette R, Yaskin J. **Comparison of GE Centricity electronic medical record database and National Ambulatory Medical Care Survey findings on the prevalence of major conditions in the United States.** *Popul Health Manag.* 2010;13(3):139-150.

Rizzo J, Gunnarsson C, Zyczynski T, Ryan A. **Methods for imputing health care expenditure data across operational databases: evidence based decision making through innovations with database visualization.** Podium presentation at *ISPOR - 15th Annual International Meeting* May 15-19, 2010, Atlanta, GA, USA.

Crawford A, Gunnarsson C, Haas K, Nigam S, Couto J. **The utilization of outpatient electronic health record systems data for outcomes and quality research: Strengths, weaknesses and lessons learned: a case study using the GE Centricity EHR.** Podium presentation at *ISPOR - 14th Annual International Meeting* May 16-20, 2009, Orlando, FL, USA.

Gunnarsson C, Ross S. **Health technology assessments in Asian-Pacific countries.** Podium presentation at *ISPOR - 3rd Asia-Pacific Conference* September 7-9, 2008, Seoul, South Korea.

Therapeutic nutritional products: Use of evidence-based medicine to support health claims. *Worldnutra 2005 - 6th International Conference & Exhibition on Nutraceuticals and Functional Foods* October 16-19, 2005, Anaheim, CA, USA.

Rheumatology

Teeple A, Ryan M, Muirheid L, Ellis L. **Healthcare Resource Utilization and Infection Risk in Rheumatoid Arthritis Patients with and without Comorbidities.** *Ann Rheum Dis.* 2016;75(Suppl2):644.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. **The Employee Absenteeism Costs of Rheumatoid Arthritis: Evidence from US National Survey Data.** *J Occup Environ Med.* 2015;57(6):635-642.

David G, Tandon N, Waters HC, Gunnarsson C, Kavanaugh A. **Rheumatoid Arthritis and Joint Replacement: Impact of Biologics.** *Am J Pharm Benefits.* 2014;6(6):256-264.

Carter C, Haas S, Gunnarsson C, Martin S. **Comparison of methods for the evaluation of ustekinumab dosing and costs in pharmacy claims databases.** *Value Health.* 2012;15(4):A162-A163.

Carter C, Haas S, Gunnarsson C, Martin S. **Longitudinal analysis of ustekinumab dosing in patients with or without prior biologic experience in the Wolters Kluwer Source® Lx National Health Claims Database.** *Value Health.* 2012;15(4):A16.

Ellis L, Haas S, Tandon N. **Dosing and refill compliance in ankylosing spondylitis patients treated with golimumab.** *Value Health.* 2012;15(4):A105.

Ellis L, Haas S, Tandon N. **Observed dosing and refill compliance in psoriatic arthritis patients treated with golimumab.** *Value Health.* 2012;15(4):A41.

Ellis L, Haas S, Tandon N. **Golimumab dosing and refill compliance patterns in rheumatoid arthritis.** *Value Health.* 2012;15(4):A40.

Schmeichel-Mueller S, Gunnarsson C, Martin S. **Determining accurate dosing of ustekinumab from Specialty Pharmacy data.** *Value Health.* 2012;15(4):A254.

Tandon N, Haas S, Bolge S, Gunnarsson C. **Patient characteristics and golimumab utilization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients.** *Value Health.* 2012;15(4):A48.

Tandon N, Haas S, Waters H, Olson W, Bolge S, Gunnarsson C. **Persistency with subcutaneous anti-TNF therapy for treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients.** *Value Health.* 2012;15(4):A41.

Tandon N, David G, Kavanaugh A, Gunnarsson C. **The impact of biologics for the treatment of rheumatoid arthritis.** *J Manag Care Pharm.* 2012;18(2):181-182.

Tandon N, David G, Kavanaugh A, Gunnarsson C. **The impact of biologics for the treatment of rheumatoid arthritis: the case of total hip and knee replacement surgery.** *Arthritis Rheum.* 2011;63(10 Suppl):912.

Ellis L, Ryan A, Haas S, Gunnarsson C, Tandon, N. **Longitudinal analysis of golimumab utilization: evidence from the Wolters Kluwer Source LX National Health Claims Database.** *J Manag Care Pharm.* 2011;17(7):562-563.

Ellis L, Tandon N, Mody S, Doshi D, Beak C, Gunnarsson CL. **Characteristics of golimumab utilization and costs in a specialty pharmacy provider (SPP) setting.** *Value Health.* 2011;14(3):A70.

Tandon N, Saulnier A, Gunnarsson CL. **Characteristics of golimumab utilization in a large national payer database.** *Value Health.* 2011;14(3):A71.

Tandon N, Carter C, Haas S, Gunnarsson CL. **GE Centricity electronic medical records study: comorbidities and biologic experience among patients receiving golimumab.** *Value Health.* 2011;14(3):A70-A71.

Carter C, Haas S, Gunnarsson CL, Rizzo JA, Ingham M. **Longitudinal analysis of infliximab dosing and infusion intervals across 30 infusions.** *Value Health.* 2011;14(3):A70.

Carter C, Gunnarsson CL, Rizzo JA, Bolge S, Ingham M. **Economic consequences of under-utilization with tumor necrosis factor inhibitors in rheumatoid arthritis patients.** *Value Health.* 2011;14(3):A70.

Carter CT, Rizzo JA, Gunnarsson CL, Bolge SC. **Consistency of maintenance infliximab weight-based dosing and administration patterns in commercially insured patients with rheumatoid arthritis.** *J Manag Care Pharm.* 2011;17(3):240.

Carter C, Rizzo J, Gunnarsson CL, Bolge SC, Mody SH. **Rates and economic consequences of rheumatoid arthritis patients receiving less-than-recommended labeled dosing of adalimumab and etanercept.** *J Manag Care Pharm.* 2010;16(7):544-545.

Rizzo J, Gunnarsson C, Fang H, Carter C, Bolge S, Mody S. **Differences in demographics and pre-index health care utilization and costs in patients with rheumatoid arthritis taking anti-TNF biologics during the first year of persistent therapy.** *Value Health.* 2010;13(3):A134.

Rizzo J, Gunnarsson C, Fang H, Carter C, Bolge S. **Alternative approaches for estimating drug dosing in the treatment of rheumatoid arthritis: the case of infliximab.** *Value Health.* 2010;13(3):A134.

Rizzo J, Gunnarsson C, Fang H, Carter C, Bolge S, McKenzie RS. **An event-level analysis of prescription refill intervals for adalimumab and etanercept in the treatment of rheumatoid arthritis.** *Value Health.* 2010;13(3):A128.

Bolge S, Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J. **The direct medical costs of rheumatoid arthritis: evidence from United States national survey data.** *Value Health.* 2010;13(3):A124.

Naim A, Lofland J, Bolge S, Rizzo J, Gunnarsson C, Chen J. **The indirect costs associated with absenteeism of working adults with rheumatoid arthritis: evidence from United States national survey data.** *Value Health.* 2010;13(3):A124.

Transplantation

Irish W. **Conducting Clinical Studies in Low Incidence/Rare Conditions: Scientific Challenges and Study Design Considerations.** Oral presentation at *Antibody Mediated Rejection in Kidney Transplantation; Public Workshop*, April 12-13, 2017, Silver Spring, MD, USA.

Tedesco H, Irish W, Dharmesh K, Patel D, Cibrik D. **Comparison of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant (Ktx).** *Am J Transplant.* 2017;17(suppl 3):740.

Ojo A, Agashivala N, Gache L, Irish W. **Twenty Year Trends in Outcomes and Costs Following Kidney Transplantation.** *Am J Transplant.* 2017;17(suppl 3):390-391.

Irish W, Ojo AO, Agashivala N, Gache LM. **20-Year Trends in Clinical Outcomes of Kidney Transplantation.** *J Am Soc Nephrol.* 2016;27:45A.

Cibrik D, Irish W, McCague KM, Patel D, Tedesco-Silva H. **Long-Term Outcomes with Everolimus (EVR) and Other Regimens in Kidney Transplantation in the United States.** *J Am Soc Nephrol.* 2016;27:621A.

Lee E, Perry AR, Facklam D, Schwartz JJ, Franks B, Thal G, Spalding JR, Vassilakis ME, Irish W. **Impact of Tacrolimus Formulation Switching on Trough Variability.** *J Am Soc Nephrol.* 2016;27:619A.